OBJECTIVE: To evaluate the safety and efficacy of daclatasvir, an HCV NS5A inhibitor with pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin. DESIGN: In this Phase 2b double-blind, placebo-controlled study, treatment-naive adults with HCV genotype 1 (N=365) or 4 (N=30) infection were randomly assigned (2:2:1) to daclatasvir 20 mg or 60 mg, or placebo once daily plus weekly peginterferon-alfa-2a and twice-daily ribavirin. Daclatasvir recipients achieving protocol-defined response (PDR; HCV-RNA

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

BRUNETTO, MAURIZIA ROSSANA;
2015

Abstract

OBJECTIVE: To evaluate the safety and efficacy of daclatasvir, an HCV NS5A inhibitor with pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin. DESIGN: In this Phase 2b double-blind, placebo-controlled study, treatment-naive adults with HCV genotype 1 (N=365) or 4 (N=30) infection were randomly assigned (2:2:1) to daclatasvir 20 mg or 60 mg, or placebo once daily plus weekly peginterferon-alfa-2a and twice-daily ribavirin. Daclatasvir recipients achieving protocol-defined response (PDR; HCV-RNA
Hézode, C; Hirschfield, Gm; Ghesquiere, W; Sievert, W; Rodriguez Torres, M; Shafran, Sd; Thuluvath, Pj; Tatum, Ha; Waked, I; Esmat, G; Lawitz, Ej; Rustgi, Vk; Pol, S; Weis, N; Pockros, Pj; Bourlière, M; Serfaty, L; Vierling, Jm; Fried, Mw; Weiland, O; Brunetto, MAURIZIA ROSSANA; Everson, Gt; Zeuzem, S; Kwo, Py; Sulkowski, M; Bräu, N; Hernandez, D; Mcphee, F; Wind Rotolo, M; Liu, Z; Noviello, S; Hughes, Ea; Yin, Pd; Schnittman, S.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11568/844222
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 34
  • Scopus 101
  • ???jsp.display-item.citation.isi??? 86
social impact